We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+31.01%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$570M
AUM Growth
+$85.9M
Cap. Flow
-$10.1M
Cap. Flow %
-1.78%
Top 10 Hldgs %
79.11%
Holding
57
New
1
Increased
2
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$46.1M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$2.79M
3
CYPH
Cypherpunk Technologies Inc
CYPH
+$2.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.4M
2
ACLX
Arcellx
ACLX
+$11.3M
3
VRNA
Verona Pharma
VRNA
+$7.41M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$6.52M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.78M 0.49%
881,450
– –
RAIN
27
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$2.44M 0.43%
2,034,552
-226,100
-10% -$1.13M
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$2.35M 0.41%
196,425
– –
TNGX icon
29
Tango Therapeutics
TNGX
$4.72B
$2.09M 0.37%
630,000
– –
IOBT
30
DELISTED
IO Biotech
IOBT
$1.97M 0.35%
1,008,437
– –
CYPH
31
Cypherpunk Technologies Inc
CYPH
$71.7M
$1.88M 0.33%
602,203
+517,599
+612% +$2.6M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$1.77M 0.31%
202,348
– –
IGMS
33
DELISTED
IGM Biosciences
IGMS
$1.43M 0.25%
154,664
– –
BOLT icon
34
Bolt Biotherapeutics
BOLT
$7.44M
$1.34M 0.24%
52,458
– –
ELEV
35
DELISTED
Elevation Oncology
ELEV
$1.26M 0.22%
830,565
– –
VTVT icon
36
vTv Therapeutics
VTVT
$136M
$1.21M 0.21%
40,888
– –
TIL icon
37
Instil Bio
TIL
$49.4M
$985K 0.17%
89,414
– –
VIRX
38
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$972K 0.17%
689,709
– –
ALLK
39
DELISTED
Allakos
ALLK
$750K 0.13%
172,089
– –
SYRE icon
40
Spyre Therapeutics
SYRE
$9.12B
$398K 0.07%
35,349
– –
KLRS
41
Kalaris Therapeutics
KLRS
$99.7M
$280K 0.05%
3,580
– –
ATXS
42
DELISTED
Astria Therapeutics
ATXS
$208K 0.04%
25,000
– –
SNCE
43
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$191K 0.03%
45,000
– –
NVAX icon
44
Novavax
NVAX
$1.27B
$158K 0.03%
21,244
– –
KRON
45
DELISTED
Kronos Bio
KRON
$134K 0.02%
78,131
– –
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$22.1K ﹤0.01%
133,333
– –
SRZNW icon
47
Surrozen Inc Warrant
SRZNW
$22.4K
$5.52K ﹤0.01%
99,999
– –
ALXO icon
48
ALX Oncology
ALXO
$284M
– –
-262,786
Closed -$1.19M
CNTA
49
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,693,736
Closed -$6.52M
EQ icon
50
Equillium
EQ
$134M
– –
-615,541
Closed -$449K
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2023 Portfolio in Review

As of Q2 2023, Samsara BioCapital held 57 positions worth $570M, up 18% from $484M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Samsara BioCapital's Q2 2023 filing shows 1 new, 2 increased, 9 reduced and 10 closed positions. Its largest new stake was ACELYRIN: 2,256,022 shares worth $47.2M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Samsara BioCapital's largest Q2 2023 buy was ACELYRIN: 2,256,022 shares worth $47.2M.
  • Samsara BioCapital added most to LYRA THERAPEUTICS INC in Q2 2023, an estimated $2.79M increase.
  • Samsara BioCapital's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $13.4M.
  • Samsara BioCapital fully exited Centessa Pharmaceuticals in Q2 2023, selling an estimated $6.52M.
  • Samsara BioCapital's ten largest holdings make up 79% of its $570M portfolio in Q2 2023.
  • Samsara BioCapital opened 1 new position and closed 10 in Q2 2023.
  • Samsara BioCapital's portfolio value rose 18% quarter-over-quarter to $570M.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.